Relevant Articles About Prostate Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to evaluate ccfDNA, mtDNA, and CTCs as treatment response biomarkers and their link to EMT. The results showed plasma ccfDNA and mtDNA are potential biomarkers for monitoring chemotherapy response in breast cancer. Breast cancer is the...
KEY TAKEAWAYS The study aimed to evaluate the TNBC-DX test's ability to predict response to neoadjuvant taxane-carboplatin chemotherapy in eTNBC. The primary endpoints were to determine pCR, DDFS, and OS. Researchers found the TNBC-DX test predicts response to...
KEY TAKEAWAYS The SOLARIS phase 3 trial investigated the effect of high-dose vitamin D3 on PFS in patients with mCRC. Researchers found that high-dose vitamin D3 showed no overall benefit for PFS but may help patients with mCRC. Higher 25-hydroxyvitamin D levels...
The EMBARK phase 3 trial aimed to examine nursing implications of efficacy, safety, and PROs for enzalutamide treatments. The primary endpoint was MFS. …
The PROREPAIR-B, PROSENZA, PROSTAC, and PROSABI observational trial aimed to investigate the impact of HRR gene mutations beyond BRCA2 in patients with mCRPC. …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …